{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T22:10:26Z","timestamp":1761516626325,"version":"build-2065373602"},"reference-count":27,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2019,11,1]],"date-time":"2019-11-01T00:00:00Z","timestamp":1572566400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,11,1]],"date-time":"2019-11-01T00:00:00Z","timestamp":1572566400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["aacejournalendocrinepractice.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Endocrine Practice"],"published-print":{"date-parts":[[2019,11]]},"DOI":"10.4158\/ep-2018-0615","type":"journal-article","created":{"date-parts":[[2019,6,26]],"date-time":"2019-06-26T10:51:38Z","timestamp":1561546298000},"page":"1091-1100","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Efficacy and Safety of Iglarlixi in Hispanics and Non-Hispanic Whites with Type 2 Diabetes"],"prefix":"10.1016","volume":"25","author":[{"given":"Pablo F.","family":"Mora","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jason","family":"Chao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aramesh","family":"Saremi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Terry A.","family":"Dex","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michelle","family":"Roberts","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guillermo E.","family":"Umpierrez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"year":"2017","series-title":"IDF Diabetes Atlas","author":"International Diabetes Federation (IDF)","key":"10.4158\/EP-2018-0615_bb0010"},{"key":"10.4158\/EP-2018-0615_bb0015","doi-asserted-by":"crossref","first-page":"329","DOI":"10.3389\/fpubh.2017.00329","article-title":"The genetic basis of type 2 diabetes in Hispanics and Latin Americans: challenges and opportunities","volume":"5","author":"Mercader","year":"2017","journal-title":"Front Public Health"},{"year":"2017","series-title":"National Diabetes Statistics Report, 2017","author":"Centers for Disease Control and Prevention (CDC)","key":"10.4158\/EP-2018-0615_bb0020"},{"key":"10.4158\/EP-2018-0615_bb0025","series-title":"Current Population Reports","article-title":"Demographic turning points for the United States: population projections for 2020 to 2060","author":"Vespa","year":"2018"},{"key":"10.4158\/EP-2018-0615_bb0030","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1515\/dmdi-2014-0023","article-title":"Pharmacogenetics of drug-metabolizing enzymes in US Hispanics","volume":"30","author":"Claudio-Campos","year":"2015","journal-title":"Drug Metab Pers Ther"},{"key":"10.4158\/EP-2018-0615_bb0035","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1007\/s40142-013-0017-3","article-title":"Genetics of population differences in drug response","volume":"1","author":"Bachtiar","year":"2013","journal-title":"Curr Genet Med Rep"},{"key":"10.4158\/EP-2018-0615_bb0040","doi-asserted-by":"crossref","DOI":"10.1155\/2014\/926713","article-title":"Genetics of type 2 diabetes: insights into the pathogenesis and its clinical application","volume":"2014","author":"Sun","year":"2014","journal-title":"Biomed Res Int"},{"key":"10.4158\/EP-2018-0615_bb0045","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1002\/cpt.61","article-title":"Racial\/ethnic differences in drug disposition and response: review of recently approved drugs","volume":"97","author":"Ramamoorthy","year":"2015","journal-title":"Clin Pharmacol Ther"},{"key":"10.4158\/EP-2018-0615_bb0050","doi-asserted-by":"crossref","first-page":"2003","DOI":"10.1056\/NEJMp1511294","article-title":"Will precision medicine move us beyond race?","volume":"374","author":"Bonham","year":"2016","journal-title":"N Engl J Med"},{"key":"10.4158\/EP-2018-0615_bb0055","doi-asserted-by":"crossref","first-page":"818","DOI":"10.4158\/EP09285.OR","article-title":"Impact of race\/ethnicity on the efficacy and safety of commonly used insulin regimens: a post hoc analysis of clinical trials in type 2 diabetes mellitus","volume":"16","author":"Davidson","year":"2010","journal-title":"Endocr Pract"},{"key":"10.4158\/EP-2018-0615_bb0060","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1111\/dom.12927","article-title":"Glycaemic control and hypoglycaemia burden in patients with type 2 diabetes initiating basal insulin in Europe and the USA","volume":"19","author":"Mauricio","year":"2017","journal-title":"Diabetes Obes Metab"},{"key":"10.4158\/EP-2018-0615_bb0065","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1007\/s13300-017-0280-5","article-title":"Achievement of glycated hemoglobin goals in the US remains unchanged through 2014","volume":"8","author":"Carls","year":"2017","journal-title":"Diabetes Ther"},{"key":"10.4158\/EP-2018-0615_bb0070","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1007\/s13300-018-0413-5","article-title":"Probability of achieving glycemic control with basal insulin in patients with type 2 diabetes in real-world practice in the USA","volume":"9","author":"Blonde","year":"2018","journal-title":"Diabetes Ther"},{"key":"10.4158\/EP-2018-0615_bb0075","doi-asserted-by":"crossref","first-page":"2669","DOI":"10.2337\/dci18-0033","article-title":"Management of hyperglycemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)","volume":"41","author":"Davies","year":"2018","journal-title":"Diabetes Care"},{"key":"10.4158\/EP-2018-0615_bb0080","doi-asserted-by":"crossref","first-page":"91","DOI":"10.4158\/CS-2017-0153","article-title":"Consensus statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the comprehensive type 2 diabetes management algorithm \u2013 2018 executive summary","volume":"24","author":"Garber","year":"2018","journal-title":"Endocr Pract"},{"key":"10.4158\/EP-2018-0615_bb0085","doi-asserted-by":"crossref","first-page":"773","DOI":"10.2337\/db09-9028","article-title":"Banting lecture: From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus","volume":"58","author":"DeFronzo","year":"2009","journal-title":"Diabetes"},{"key":"10.4158\/EP-2018-0615_bb0090","doi-asserted-by":"crossref","first-page":"1972","DOI":"10.2337\/dc16-1495","article-title":"Efficacy and safety of LixiLan, a titratable fixed-ratio combination of insulin glargine plus lixisenatide in type 2 diabetes inadequately controlled on basal insulin and metformin: the LixiLan-L randomized trial","volume":"39","author":"Aroda","year":"2016","journal-title":"Diabetes Care"},{"key":"10.4158\/EP-2018-0615_bb0095","doi-asserted-by":"crossref","first-page":"2026","DOI":"10.2337\/dc16-0917","article-title":"Benefits of LixiLan, a titratable fixed-ratio combination of insulin glargine plus lixisenatide, versus insulin glargine and lixisenatide monocomponents in type 2 diabetes inadequately controlled on oral agents: the LixiLan-O randomized trial","volume":"39","author":"Rosenstock","year":"2016","journal-title":"Diabetes Care"},{"key":"10.4158\/EP-2018-0615_bb0100","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1111\/dom.13108","article-title":"Initiating therapy in patients newly diagnosed with type 2 diabetes: combination therapy vs a stepwise approach","volume":"20","author":"Cersosimo","year":"2018","journal-title":"Diabetes Obes Metab"},{"key":"10.4158\/EP-2018-0615_bb0105","unstructured":"Sanofi. Soliqua 100\/33 (insulin glargine and lixisenatide injection): prescribing information. Bridgewater, NJ: Sanofi. Available at: http:\/\/products.sanofi.us\/soliqua100-33\/soliqua100-33.pdf. Accessed March 13, 2019."},{"key":"10.4158\/EP-2018-0615_bb0110","series-title":"Health, United States, 2016","first-page":"236","article-title":"Table 58: Normal weight, overweight, and obesity among adults aged 20 and over, by selected characteristics: United States, selected years 1988\u20131994 through 2011\u20132014","author":"Centers for Disease Control and Prevention (CDC)","year":"2016"},{"key":"10.4158\/EP-2018-0615_bb0115","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1016\/j.clinthera.2013.12.016","article-title":"Characterization of type 2 diabetes mellitus by age and ethnic groups based on a nationwide survey","volume":"36","author":"Lopez","year":"2014","journal-title":"Clin Ther"},{"key":"10.4158\/EP-2018-0615_bb0120","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.2337\/dc12-2258","article-title":"The prevalence of meeting A1C, blood pressure, and LDL goals among people with diabetes, 1988\u20132010","volume":"36","author":"Stark Casagrande","year":"2013","journal-title":"Diabetes Care"},{"key":"10.4158\/EP-2018-0615_bb0125","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1111\/1753-0407.12410","article-title":"Clinical inertia causing new or progression of diabetic retinopathy in type 2 diabetes: a retrospective cohort study","volume":"9","author":"Osataphan","year":"2017","journal-title":"J Diabetes"},{"key":"10.4158\/EP-2018-0615_bb0130","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1177\/1479164116679775","article-title":"Gaps and barriers in the control of blood glucose in people with type 2 diabetes","volume":"14","author":"Blonde","year":"2017","journal-title":"Diab Vasc Dis Res"},{"key":"10.4158\/EP-2018-0615_bb0135","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1111\/dom.12626","article-title":"Clinical inertia with regard to intensifying therapy in people with type 2 diabetes treated with basal insulin","volume":"18","author":"Khunti","year":"2016","journal-title":"Diabetes Obes Metab"},{"key":"10.4158\/EP-2018-0615_bb0140","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1111\/j.1464-5491.2012.03605.x","article-title":"Insulin adherence behaviours and barriers in the multinational Global Attitudes of Patients and Physicians in Insulin Therapy study","volume":"29","author":"Peyrot","year":"2012","journal-title":"Diabet Med"}],"container-title":["Endocrine Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1530891X2035134X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1530891X2035134X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T22:05:33Z","timestamp":1761516333000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1530891X2035134X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11]]},"references-count":27,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2019,11]]}},"alternative-id":["S1530891X2035134X"],"URL":"https:\/\/doi.org\/10.4158\/ep-2018-0615","relation":{},"ISSN":["1530-891X"],"issn-type":[{"type":"print","value":"1530-891X"}],"subject":[],"published":{"date-parts":[[2019,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and Safety of Iglarlixi in Hispanics and Non-Hispanic Whites with Type 2 Diabetes","name":"articletitle","label":"Article Title"},{"value":"Endocrine Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.4158\/EP-2018-0615","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2019 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}